AZD0516

DRUG2 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Metastatic Prostate Cancer

Phase 1

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

RecruitingNCT07181161

AstraZenecaMetastatic Prostate Cancer

Start: 2025-10-01End: 2029-01-18Target: 177Updated: 2026-03-06

A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Metastatic Prostate Cancer.

Not yet recruitingCTIS2024-520026-11-00

AstraZeneca ABMetastatic Prostate Cancer

Target: 107Updated: 2025-12-15